Biological connotation of "phlegm-turbidity" theory in hepatocellular carcinoma microenvironment based on abnormal lipid metabolism

Fangming YANG; Zhun XIAO; Xiaoqi CHEN; Chuanlei ZHANG; Xinju CHEN; Suping MA; Wenxia ZHAO

doi:10.3969/j.issn.1001-5256.2023.02.029

Volume 39 Issue 2

Feb. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(2): 432-438

PDF( 3964 KB)

Biological connotation of "phlegm-turbidity" theory in hepatocellular carcinoma microenvironment based on abnormal lipid metabolism

DOI: 10.3969/j.issn.1001-5256.2023.02.029

1.
Department of Hepatology and Spleen-Stomach, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China
2.
Henan University of Chinese Medicine, Zhengzhou 450000, China

Research funding:

National Science and Technology Major Project (SQ2018ZX100303);

National Natural Science Foundation of China (82205021);

The Second Batch of Discipline Construction Projects of Traditional Chinese Medicine in Henan Province's Characteristic Backbone Discipline (STG-ZYX01-202101);

Henan Province Traditional Chinese Medicine Scientific Research Special Project (2022JDZX018);

The Doctoral Research Foundation of the First Affiliated Hospital of Henan University of Traditional Chinese Medicine (2021BSJJ007)

More Information

Corresponding author: ZHAO Wenxia, zhao-wenxia@163.com (ORCID: 0000-0001-6666-9469)
Received Date: 2022-06-21
Accepted Date: 2022-08-18
Published Date: 2023-02-20

Abstract

Abstract

There is still a lack of effective strategies for the prevention and treatment of liver cancer, and a deep understanding of its pathogenesis may help to develop new treatment methods. Due to the abnormal changes of lipid metabolism in the development and progression of liver cancer, such process is closely associated with the "phlegm-turbidity" theory in traditional Chinese medicine (TCM). Starting from the changes of lipid metabolism in hepatocellular carcinoma microenvironment, this article discusses the association of the abnormal changes of lipid metabolism in tumor cells and immune cells with the "phlegm-turbidity" theory and the clinical efficacy of phlegm-eliminating therapies in clinical practice. Since the "phlegm-turbidity" theory in TCM plays an important role in the pathogenesis and pathological changes of liver cancer, the analysis of its theoretical connotation helps to clarify pathological mechanism, thereby providing a theoretical basis for the role of TCM in the prevention and treatment of liver cancer.
- Carcinoma, Hepatocellular,
- Lipid Metabolism,
- Phlegm Turbidity,
- Medicine, Chinese Traditional

FullText(HTML)

References(44)

References

[1]	TAHMASEBI BIRGANI M, CARLONI V. Tumor microenvironment, a paradigm in hepatocellular carcinoma progression and therapy[J]. Int J Mol Sci, 2017, 18(2): 405. DOI: 10.3390/ijms18020405.
[2]	ZHUANG TZ, CHEN YB, AN HY. Discussion on TCM differentiation of primary liver cancer[J]. Forum Tradit Chin Med, 2021, 36(1): 18-19. DOI: 10.13913/j.cnki.41-1110/r.2021.01.008. 庄桐粧, 陈钰冰, 安海燕. 原发性肝癌中医辨证探讨[J]. 国医论坛, 2021, 36(1): 18-19. DOI: 10.13913/j.cnki.41-1110/r.2021.01.008.
[3]	BAO MH, WONG CC. Hypoxia, metabolic reprogramming, and drug resistance in liver cancer[J]. Cells, 2021, 10(7): 1715. DOI: 10.3390/cells10071715.
[4]	ZHAO WX, CHEN XJ. Principles and regimens for traditional Chinese medicine diagnosis and treatment of primary liver cancer[J]. J Clin Hepatol, 2021, 37(9): 2005-2008. DOI: 10.3969/j.issn.1001-5256.2021.09.002. 赵文霞, 陈欣菊. 原发性肝癌中医药诊疗原则及方案构建[J]. 临床肝胆病杂志, 2021, 37(9): 2005-2008. DOI: 10.3969/j.issn.1001-5256.2021.09.002.
[5]	GU KB, ZHANG LN, WU J, et al. Research progress on resolving phlegm method on the treatment of malignant tumors[J]. China J Tradit Chin Med Pharma, 2017, 32(12): 5468-5471. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201712062.htm 顾恪波, 张丽娜, 吴洁, 等. "化痰"法治疗恶性肿瘤的研究进展[J]. 中华中医药杂志, 2017, 32(12): 5468-5471. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201712062.htm
[6]	LU C, RONG D, ZHANG B, et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities[J]. Mol Cancer, 2019, 18(1): 130. DOI: 10.1186/s12943-019-1047-6.
[7]	ZHANG JS. A preliminary study on the treatment of hyperlipidemia from the liver[J]. J New Chin Med, 2006, 38(11): 6-9. DOI: 10.3969/j.issn.0256-7415.2006.11.003. 张金生. 高脂血症从肝论治初探[J]. 新中医, 2006, 38(11): 6-9. DOI: 10.3969/j.issn.0256-7415.2006.11.003.
[8]	XUE X, LI HY, LI YM, et al. Study on the mechanism of treating fatty liver from phleg[J]. Chin J Basic Med Tradit Chin Med, 2014, 20(11): 1472-1475. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201411009.htm 薛欣, 李海玉, 李玉梅, 等. 从痰论治脂肪肝机制探讨[J]. 中国中医基础医学杂志, 2014, 20(11): 1472-1475. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201411009.htm
[9]	HALL Z, CHIARUGI D, CHARIDEMOU E, et al. Lipid remodeling in hepatocyte proliferation and hepatocellular carcinoma[J]. Hepatology, 2021, 73(3): 1028-1044. DOI: 10.1002/hep.31391.
[10]	HU B, LIN JZ, YANG XB, et al. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review[J]. Cell Prolif, 2020, 53(3): e12772. DOI: 10.1111/cpr.12772.
[11]	FUJIWARA N, NAKAGAWA H, ENOOKU K, et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity[J]. Gut, 2018, 67(8): 1493-1504. DOI: 10.1136/gutjnl-2017-315193.
[12]	LU GD, ANG YH, ZHOU J, et al. CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma[J]. Hepatology, 2015, 61(3): 965-978. DOI: 10.1002/hep.27593.
[13]	SENNI N, SAVALL M, CABRERIZO GRANADOS D, et al. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids[J]. Gut, 2019, 68(2): 322-334. DOI: 10.1136/gutjnl-2017-315448.
[14]	NAKAGAWA H, HAYATA Y, KAWAMURA S, et al. Lipid metabolic reprogramming in hepatocellular carcinoma[J]. Cancers (Basel), 2018, 10(11): 447. DOI: 10.3390/cancers10110447.
[15]	ZENG ZR, CHEN MH, WANG GW. WangGuowei's Clinical Experience in Treating Hepatitis from Perspective of Heat-Damp Theory[J]. J Chengdu Univ Tradit Chin Med, 2021, 44(2): 66-69. DOI: 10.13593/j.cnki.51-1501/r.2021.02.066. 曾振锐, 陈敏华, 王国玮. 王国玮从湿热论治肝炎临床经验撷要[J]. 成都中医药大学学报, 2021, 44(2): 66-69. DOI: 10.13593/j.cnki.51-1501/r.2021.02.066.
[16]	CHO HK, KIM SY, YOO SK, et al. Fatty acids increase hepatitis B virus X protein stabilization and HBx-induced inflammatory gene expression[J]. FEBS J, 2014, 281(9): 2228-2239. DOI: 10.1111/febs.12776.
[17]	KIM KH, HONG SP, KIM K, et al. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma[J]. Biochem Biophys Res Commun, 2007, 355(4): 883-888. DOI: 10.1016/j.bbrc.2007.02.044.
[18]	IOANNOU GN. Epidemiology and risk-stratification of NAFLD-associated HCC[J]. J Hepatol, 2021, 75(6): 1476-1484. DOI: 10.1016/j.jhep.2021.08.012.
[19]	GUO J, YE LL, GUO YQ, et al. Discussion on the differentiation and treatment of nonalcoholic fatty liver from the perspective of 'turbidity and coagulation'[J]. China J Tradit Chin Med Pharma, 2020, 35(4): 1885-1887. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202004072.htm 郭静, 叶琳琳, 郭玉琴, 等. 从"浊阴凝痞"视角探讨非酒精性脂肪肝病辨治思路[J]. 中华中医药杂志, 2020, 35(4): 1885-1887. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202004072.htm
[20]	SANGINETO M, VILLANI R, CAVALLONE F, et al. Lipid metabolism in development and progression of hepatocellular carcinoma[J]. Cancers (Basel), 2020, 12(6): 1419. DOI: 10.3390/cancers12061419.
[21]	LI Z, GUAN M, LIN Y, et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by liver lipidomics[J]. Int J Mol Sci, 2017, 18(12): 2550. DOI: 10.3390/ijms18122550.
[22]	BERNDT N, ECKSTEIN J, HEUCKE N, et al. Characterization of lipid and lipid droplet metabolism in human HCC[J]. Cells, 2019, 8(5): 512. DOI: 10.3390/cells8050512.
[23]	PAVLOVA NN, THOMPSON CB. The emerging hallmarks of cancer metabolism[J]. Cell Metab, 2016, 23(1): 27-47. DOI: 10.1016/j.cmet.2015.12.006.
[24]	YANG YF, LIU JT. Study on biomarkers of phlegm dampness syndrome in metabolic syndrome based on metabonomics[J]. Lishizhen Med Mater Med Res, 2020, 31(2): 509-512. https://www.cnki.com.cn/Article/CJFDTOTAL-SZGY202002085.htm 杨宇峰, 刘军彤. 基于代谢组学的代谢综合征痰湿证生物标志物研究[J]. 时珍国医国药, 2020, 31(2): 509-512. https://www.cnki.com.cn/Article/CJFDTOTAL-SZGY202002085.htm
[25]	WANG Q, DONG J, WU HD, et al. Molecular biological characteristics of phlegm dampness constitution[J]. Strat Study Chin Acad Engin, 2008, 10(7): 100-103. https://www.cnki.com.cn/Article/CJFDTOTAL-GCKX200807018.htm 王琦, 董静, 吴宏东, 等. 痰湿体质的分子生物学特征[J]. 中国工程科学, 2008, 10(7): 100-103. https://www.cnki.com.cn/Article/CJFDTOTAL-GCKX200807018.htm
[26]	LI Z, WU T, ZHENG B, et al. Individualized precision treatment: Targeting TAM in HCC[J]. Cancer Lett, 2019, 458: 86-91. DOI: 10.1016/j.canlet.2019.05.019.
[27]	SU P, WANG Q, BI E, et al. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages[J]. Cancer Res, 2020, 80(7): 1438-1450. DOI: 10.1158/0008-5472.CAN-19-2994.
[28]	ZHANG Q, LOU Y, BAI XL, et al. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression[J]. World J Gastroenterol, 2018, 24(31): 3500-3512. DOI: 10.3748/wjg.v24.i31.3500.
[29]	PACELLA I, PROCACCINI C, FOCACCETTI C, et al. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth[J]. Proc Natl Acad Sci U S A, 2018, 115(28): E6546-E6555. DOI: 10.1073/pnas.1720113115.
[30]	TRAN JANCO JM, LAMICHHANE P, KARYAMPUDI L, et al. Tumor-infiltrating dendritic cells in cancer pathogenesis[J]. J Immunol, 2015, 194(7): 2985-2991. DOI: 10.4049/jimmunol.1403134.
[31]	EVERTS B, AMIEL E, HUANG SC, et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKε supports the anabolic demands of dendritic cell activation[J]. Nat Immunol, 2014, 15(4): 323-332. DOI: 10.1038/ni.2833.
[32]	WCULEK SK, KHOUILI SC, PRIEGO E, et al. Metabolic control of dendritic cell functions: digesting information[J]. Front Immunol, 2019, 10: 775. DOI: 10.3389/fimmu.2019.00775.
[33]	ZHANG SQ, HU H, LUO SJ, et al. Immune mechanism of the internal environment of spleen deficiency in liver cancer[J]. Lishizhen Med Mater Med Res, 2020, 31(8): 1961-1963. DOI: 10.3969/j.issn.1008-0805.2020.08.059 张书侨, 胡浩, 罗绍驹, 等. 肝癌脾虚内环境境免疫机制研究[J]. 时珍国医国药, 2020, 31(8): 1961-1963. DOI: 10.3969/j.issn.1008-0805.2020.08.059
[34]	ZHAO CL. "Liver controlling conveyance and dispersion" act as the core of regulating immunologic function[J]. J Tradit Chin Med, 2017, 58(7): 568-571. DOI: 10.13288/j.11-2166/r.2017.07.009. 赵昌林. 肝主疏泄为调控免疫功能的核心[J]. 中医杂志, 2017, 58(7): 568-571. DOI: 10.13288/j.11-2166/r.2017.07.009.
[35]	SUN MQ, HU KW, ZHOU T. Discussion on the related mechanism of tumor metastasis and tumor microenvironment based on phlegm[J]. Western J Traditl Chin Med, 2019, 32(10): 15-18. https://www.cnki.com.cn/Article/CJFDTOTAL-GSZY201910005.htm 孙满强, 胡凯文, 周天. 从痰论治肿瘤微环境与肿瘤转移相关作用机制[J]. 西部中医药, 2019, 32(10): 15-18. https://www.cnki.com.cn/Article/CJFDTOTAL-GSZY201910005.htm
[36]	YUAN JH, WU Y. Related theories of spleen-invigorating and phlegm-removing therapy and its application in treatment of liver cancer[J]. J Liaoning Univ Tradit Chin Med, 2012, 14(6): 85-87. DOI: 10.13194/j.jlunivtcm.2012.06.87.yuanjh.118. 袁菊花, 吴煜. 健脾化痰法在肝癌治疗中的相关理论及应用[J]. 辽宁中医药大学学报, 2012, 14(6): 85-87. DOI: 10.13194/j.jlunivtcm.2012.06.87.yuanjh.118.
[37]	SUN C, WU Y, CHEN YL, et al. Clinical effect of the phlegm-eliminating, phlegm-dissolving, and phlegm-removing methods in treatment of primary liver cancer: An analysis of 3 proven cases[J]. Jiangsu J Traditi Chin Med, 2013, 45(3): 67-68. DOI: 10.3969/j.issn.1672-397X.2013.03.044. 孙超, 吴煜, 陈永伦, 等. 治痰三法治疗原发性肝癌的探讨——附验案3则[J]. 江苏中医药, 2013, 45(3): 67-68. DOI: 10.3969/j.issn.1672-397X.2013.03.044.
[38]	LI B, WANG YH, ZHANG XF. Clinical effect of spleen-invigorating, phlegm-dissolving, and static blood-resolving prescription in treatment of advanced primary liver cancer[J]. Liaoning J Tradit Chin Med, 2014, 41(1): 108-110. DOI: 10.13192/j.issn.1000-1719.2014.01.047. 李斌, 王玉华, 张霄峰. 健脾消痰散结方治疗中晚期原发性肝癌临床观察[J]. 辽宁中医杂志, 2014, 41(1): 108-110. DOI: 10.13192/j.issn.1000-1719.2014.01.047.
[39]	LIANG Q, LUO PJ, ZENG SM, et al. Huang Gui-hua's Experience of Treating Primary Liver Cancer[J]. Henan Tradit Chin Med, 2020, 40(8): 1204-1207. DOI: 10.16367/j.issn.1003-5028.2020.08.0305. 梁琪, 罗鹏基, 曾思敏, 等. 薛博瑜治疗原发性肝癌经验[J]. 河南中医, 2020, 40(8): 1204-1207. DOI: 10.16367/j.issn.1003-5028.2020.08.0305.
[40]	YUE Y. Experience in the four methods of Professor Xue Boyu in syndrome differentiation-based treatment of liver cancer[J]. Global Tradit Chin Med, 2016, 9(1): 56-57. DOI: 10.16367/j.issn.1003-5028.2020.08.0305. 岳煜. 薛博瑜教授辨治肝癌四法经验探析[J]. 环球中医药, 2016, 9(1): 56-57. DOI: 10.16367/j.issn.1003-5028.2020.08.0305.
[41]	QIU XY, JIA LQ, SONG N, et al. Study on effect and mechanism of huayu qutan fomula on mice with high-fat and liver cancer based on ferroptosis related protein[J]. Chin Arch Tradit Chin Med, 2021, 39(9): 137-141, 273. DOI: 10.13193/j.issn.1673-7717.2021.09.035 裘雪莹, 贾连群, 宋囡, 等. 基于铁死亡相关蛋白探讨化瘀祛痰方对高脂合并肝癌小鼠的影响及机制[J]. 中华中医药学刊, 2021, 39(9): 137-141, 273. DOI: 10.13193/j.issn.1673-7717.2021.09.035.
[42]	ZHANG CA, GU YF, ZHANG YC, et al. Clinical thinking of treating recurrence and metastasis of liver cancer from phlegm[J]. J Oncol Chin Med, 2020, 2(1): 31-35. DOI: 10.19811/j.cnki.ISSN2096-6628.2020.01.008. 张慈安, 顾雨芳, 张映城, 等. 浅析从痰论治肝癌复发转移的临床思路[J]. 中医肿瘤学杂志, 2020, 2(1): 31-35. DOI: 10.19811/j.cnki.ISSN2096-6628.2020.01.008.
[43]	LI X, YU H, GONG Y, et al. Fuzheng Xiaozheng prescription relieves rat hepatocellular carcinoma through improving anti-inflammation capacity and regulating lipid related metabolisms[J]. J Ethnopharmacol, 2022, 284: 114801. DOI: 10.1016/j.jep.2021.114801.
[44]	YANG L, ZHANG X, LUO CY, et al. Research progress on mechanism of TCM based on lipid metabolism in prevention and treatment of liver cancer[J]. Global Tradit Chin Med, 2022, 15(6): 1100-1104. DOI: 10.3969/j.issn.1674-1749.2022.06.038. 杨岚, 张鑫, 罗春玉, 等. 基于脂质代谢的中医药防治肝癌作用机制研究进展[J]. 环球中医药, 2022, 15(6): 1100-1104. DOI: 10.3969/j.issn.1674-1749.2022.06.038.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2)

Get Citation

PDF

XML

Article Metrics

Article views (667) PDF downloads(51)

Biological connotation of "phlegm-turbidity" theory in hepatocellular carcinoma microenvironment based on abnormal lipid metabolism

DOI: 10.3969/j.issn.1001-5256.2023.02.029

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content